Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 827

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease

Open access
Kim, Jinkuk, Hu, Chunguang, Moufawad El Achkar, Christelle, Black, Lauren E., Douville, Julie, Larson, Austin, Pendergast, Mary K., Goldkind, Sara F., Lee, Eunjung A., Kuniholm, Ashley, Soucy, Aubrie, Vaze, Jai, Belur, Nandkishore R., Fredriksen, Kristina, Stojkovska, Iva, Tsytsykova, Alla, Armant, Myriam, DiDonato, Renata L., Choi, Jaejoon, Cornelissen, Laura, Pereira, Luis M., Augustine, Erika F., Genetti, Casie A., Dies, Kira, Barton, Brenda, Williams, Lucinda, Goodlett, Benjamin D., Riley, Bobbie L., Pasternak, Amy, Berry, Emily R., Pflock, Kelly A., Chu, Stephen, Reed, Chantal, Tyndall, Kimberly, Agrawal, Pankaj B., Beggs, Alan H., Grant, P. Ellen, Urion, David K., Snyder, Richard O., Waisbren, Susan E., Poduri, Annapurna, Park, Peter J., Patterson, Al, Biffi, Alessandra, Mazzulli, Joseph R., Bodamer, Olaf, Berde, Charles B., Yu, Timothy W.·2019·New England Journal of Medicine

Abstract

Summ a r yGenome sequencing is often pivotal in the diagnosis of rare diseases, but many of these conditions lack specific treatments.We describe how molecular diagnosis of a rare, fatal neurodegenerative condition led to the rational design, testing, and manufacture of milasen, a splice-modulating antisense oligonucleotide drug tailored to a particular patient.Proof-of-concept experiments in cell lines from the patient served as the basis for launching an "N-of-1" study of milasen within 1 year after first contact with the patient.There were no serious adverse events, and treatment was associated with objective reduction in seizures (determined by electroencephalography and parental reporting).This study offers a possible template for the rapid development of patient-customized treatments.(Funded by Mila's Miracle Foundation and others.)R are diseases in aggregate affect approximately 30 million persons in the United States alone. 1 Although next-generation sequencing is revolutionizing their diagnosis, the sheer number of distinct conditions (more than 7000 [https://globalgenes .org/ rare -list]) and the limited number of patients affected by each rare disease present major challenges for drug development.This report shows a path to personalized treatment for patients with orphan diseases.It describes the identification of a novel mutation in a child with neuronal ceroid lipofuscinosis 7 (CLN7, a form of Batten's disease), a rare and fatal neurodegenerative disease.2,3 Identification of the mutation was followed by the development and clinical deployment, within 1 year, of a tailored drug to treat the patient (Fig. 1A). Clinic a l Pr esentationA 6-year-old girl presented with the insidious onset of blindness, ataxia, seizures, and developmental regression.The parents' first concerns dated back to when the girl was 3 years of age, when her right foot began to turn inward.When she was 4 years of age, her family noticed her pulling books close to her face at bedtime.At 5 years of age, she came to medical attention because of modest language and social regression, as well as increased clumsiness and stumbling.In the months before she turned 6 years of age, the progression of symptoms accelerated, and she was The authors' full names, academic degrees, and affiliations are listed in the Appendix.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1813279

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 827

Metadata

Authors
Kim, J., Hu, C., Moufawad El Achkar, C., Black, L. E., Douville, J., Larson, A., Pendergast, M. K., Goldkind, S. F., Lee, E. A., Kuniholm, A., Soucy, A., Vaze, J., Belur, N. R., Fredriksen, K., Stojkovska, I., Tsytsykova, A., Armant, M., DiDonato, R. L., Choi, J., Cornelissen, L., Pereira, L. M., Augustine, E. F., Genetti, C. A., Dies, K., Barton, B., Williams, L., Goodlett, B. D., Riley, B. L., Pasternak, A., Berry, E. R., Pflock, K. A., Chu, S., Reed, C., Tyndall, K., Agrawal, P. B., Beggs, A. H., Grant, P. E., Urion, D. K., Snyder, R. O., Waisbren, S. E., Poduri, A., Park, P. J., Patterson, A., Biffi, A., Mazzulli, J. R., Bodamer, O., Berde, C. B., & Yu, T. W.
Venue
New England Journal of Medicine
Published
2019-10-24
Volume
381
Issue
17
Pages
1644-1652
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2979614510
Cited by
827
References
31
FWCI
41.79
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease. https://app.cochat.ai/papers/10.1056/nejmoa1813279
The paper
Kim, J., Hu, C., Moufawad El Achkar, C., Black, L. E., Douville, J., Larson, A., Pendergast, M. K., Goldkind, S. F., Lee, E. A., Kuniholm, A., Soucy, A., Vaze, J., Belur, N. R., Fredriksen, K., Stojkovska, I., Tsytsykova, A., Armant, M., DiDonato, R. L., Choi, J., . . . Yu, T. W. (2019). Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1813279

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.